AARTIPHARMAarti Pharmalabs

₹844.6-1.56%

Market Cap

₹7,654.71 Cr

Stock P/E

28.73

ROCE

17.59%

ROE

14.55%

Book Value

₹224.99

Financials

YoY Net Sales

EPS Growth

Operating Margin

You might have missed

No Recent News

No recent news available for this stock.

Shareholding

Holdings

Distribution

Promoter

Foreign Investors

Domestic Investors

Public

From Last Concall

POSITIVES

•
Standalone topline declined slightly YoY, but EBITDA and PAT rose, signaling underlying strength.
•
CDMO-CMO pipeline is robust: 21 customers, 60 active projects (33 on commercial paths, 27 development).

NEGATIVES

•
Consolidated topline declined YoY due to Ganesh Polychem JV treatment; not directly comparable with Q1 FY25.
•
Aarti USA revenue down in Q1 FY26 due to limited activities and shift of distributor business to US subsidiary.

Peers Summary

Sector Leader

Aarti Pharmalabs Ltd. demonstrates solid revenue growth and profitability metrics, positioning it favorably among its peers in the pharmaceuticals sector. The analysis identified key outperformers and underperformers, with Aarti Pharmalabs standing out for its growth trajectory and reasonable leverage, while companies like Sun Pharmaceutical Industries appear overvalued despite strong growth.

Key Points

• Aarti Pharmalabs Ltd. shows significant revenue growth of 14.17% YoY and a moderate PE ratio of 30.17, indicating good value for growth.
• Divi's Laboratories Ltd. exhibits the highest PE ratio at 73.20, suggesting it may be overvalued despite strong margins.
• Cipla Ltd. has the best ROCE at 22.77%, showcasing operational efficiency and effective capital utilization.

Top Performers

Mankind Pharma Ltd.

Strong revenue growth of 18.12% YoY and high ROE of 23.15%.

Dr. Reddy's Laboratories Ltd.

High profitability with a PE ratio of 15.50 and solid EPS growth.

Cipla Ltd.

Best ROCE at 22.77% and lower PE ratio at 23.73, indicating effective use of equity.

Explore

Watchlists

Command Palette